<DOC>
	<DOCNO>NCT01452334</DOCNO>
	<brief_summary>The purpose study determine side effect treatment monoclonal antibody anti-PD-L1 ( BMS-936559 ) subject compromise bone marrow function dose recommend use future study .</brief_summary>
	<brief_title>Safety Study Anti-Programmed Death-Ligand 1 Hematologic Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance 0 1 Subjects must histological confirmation relapse refractory hematologic malignancy Subjects nonHodgkin 's lymphoma Hodgkin lymphoma must least one measureable lesion define lymphoma response criterion . Tumor site consider measureable must receive prior radiation therapy Subjects multiple myeloma ( MM ) must detectable disease measure presence monoclonal immunoglobulin protein serum electrophoresis : IgG , IgA , IgM , ( Mprotein ≥ 0.5 g/dl serum IgD Mprotein ≥ 0.05 g/dl ) serum freelight chain 24 hour urine free light chain . Excluded subject plasmacytomas , plasma cell leukemia , nonsecretory myeloma Subjects chronic myelogenous leukemia ( CML ) must evidence Philadelphia chromosome polymerase chain reaction ( PCR ) chromosome analysis Life expectancy least 3 month For subject lymphoma , either formalin fixed tissue block 7 15 slide tumor sample ( archival fresh ) must available performance correlative study Subjects must receive least one prior chemotherapy regimen . Subjects must therapy least 4 week ( 2 week oral agent ) prior Day 1 Prior palliative radiation must complete least 2 week prior study Day 1 Toxicities relate prior therapy must return Grade 1 less , except alopecia . Peripheral neuropathy must Grade 2 less Adequate bone marrow function define : 1 . Absolute neutrophil count ≥ 1000/μl ( stable growth factor within 1 week study drug administration ) 2 . Hemoglobin ≥ 9 g/dL ( transfusion achieve level permit ) 3 . Platelet count ≥ 50 X 103/ μl ( transfusion achieve level permit ) Adequate renal parameter define Creatinine clearance ( CrCl ) &gt; 40 ml/min ( CockcroftGault formula ) Adequate hepatic parameter define : 1 . Aspartate aminotransferase ( AST ) ≤ 3 x ULN 2 . Alanine aminotransferase ( ALT ) ≤ 3 x ULN 3 . Bilirubin ≤ 1.5 x ULN ( except subject Gilbert 's Syndrome , must total bilirubin &lt; 3.0 mg/dL direct bilirubin &lt; 0.5 mg/dL ) Women child bear potential ( WOCBP ) least 70 day last dose investigational product Men woman ≥ 18 year age Subjects acute leukemia , blast phase CML , T cell lymphoblastic Burkitt lymphoma Subjects history central nervous system involvement hematologic malignancy symptom suggestive central nervous system involvement Subjects concomitant second malignancy ( except adequately treat nonmelanomatous skin cancer , ductal carcinoma situ , treat superficial bladder cancer prostate cancer situ cervical cancer ) exclude unless complete remission achieve least 3 year prior study entry additional therapy require anticipate required study period Subjects active autoimmune disease history know suspect autoimmune disease , history syndrome require systemic corticosteroid immunosuppressive medication , except subject vitiligo resolve childhood asthma/atopy A serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy whose control may jeopardize complication therapy Prior therapy anti program death1 ( antiPD1 ) , anti Programmed death ligand 1 ( antiPDL1 ) , anti Programmed death ligand 2 ( antiPDL2 ) , antiCD137 anti Cytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) antibody ( antibody drug specifically target Tcell costimulation checkpoint pathway ) Nononcology vaccine therapy prevention infectious disease ( eg seasonal flu vaccine , Human Papilloma Virus ( HPV ) vaccine ) within 4 week study drug administration Vaccination study also prohibit except administration inactivate influenza vaccine Prior organ allograft allogeneic bone marrow transplantation Positive human immunodeficiency virus ( HIV 1/2 ) know acquired immunodeficiency syndrome ( AIDS ) Positive test hepatitis B virus surface antigen ( HBsAg ) , antibody hepatitis B core Ag hepatitis C virus antibody ( confirmed Western Blot ) hepatitis C ribonucleic acid ( RNA ) serum Ejection fraction le 45 % subject prior anthracycline exposure History Grade 4 anaphylactic reaction monoclonal antibody therapy Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>